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Abstract
The genetic basis of autoantibody production is largely unknown outside of associations located in the major
histocompatibility complex (MHC) human leukocyte antigen (HLA) region. The aim of this study is the discovery of new
genetic associations with autoantibody positivity using genome-wide association scan single nucleotide polymorphism
(SNP) data in type 1 diabetes (T1D) patients with autoantibody measurements. We measured two anti-islet autoantibodies,
glutamate decarboxylase (GADA, n=2,506), insulinoma-associated antigen 2 (IA-2A, n=2,498), antibodies to the
autoimmune thyroid (Graves’) disease (AITD) autoantigen thyroid peroxidase (TPOA, n=8,300), and antibodies against
gastric parietal cells (PCA, n=4,328) that are associated with autoimmune gastritis. Two loci passed a stringent genome-
wide significance level (p,10
210): 1q23/FCRL3 with IA-2A and 9q34/ABO with PCA. Eleven of 52 non-MHC T1D loci showed
evidence of association with at least one autoantibody at a false discovery rate of 16%: 16p11/IL27-IA-2A, 2q24/IFIH1-IA-2A
and PCA, 2q32/STAT4-TPOA, 10p15/IL2RA-GADA, 6q15/BACH2-TPOA, 21q22/UBASH3A-TPOA, 1p13/PTPN22-TPOA, 2q33/
CTLA4-TPOA, 4q27/IL2/TPOA, 15q14/RASGRP1/TPOA, and 12q24/SH2B3-GADA and TPOA. Analysis of the TPOA-associated
loci in 2,477 cases with Graves’ disease identified two new AITD loci (BACH2 and UBASH3A).
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Introduction
The presence of circulating antibodies to the body’s own
antigens, namely autoantibodies, is the major hallmark of
autoimmunity, which can progress to the diagnosis of a variety
of autoimmune diseases. Autoantibodies directed to antigens in the
pancreatic islets, for example, glutamate decarboxylase (GADA)
and islet antigen-2 (IA-2A), are characteristic of type 1 diabetes
(T1D). The dynamics of T1D-associated autoantibodies in T1D
patients are complex. They are detected prior to clinical diagnosis
and often persist several years after diagnosis [1], but they can also
disappear prior to T1D diagnosis [2], and, in general, decline from
the time of diagnosis onwards. Antibodies are produced by B
lymphocytes. The success of B cell depletion therapies in slowing
beta-cell destruction in the mouse animal model [3] and more
recently the positive effects of such therapies also reported in a
clinical trial [4], demonstrate that B cells play a role in T1D
pathogenesis. However, it is also generally accepted that anti-islet
antibodies are not pathogenic themselves [5], in contrast, for
example, to autoantibodies in systemic erythematosus lupus (SLE)
[6]. The report of a T1D patient with a severe hereditary B cell
deficiency [7], and the fact that in animal models of T1D the
disease is transferable to healthy recipients by T cells but not by
serum [8], are consistent with this view.
B cell maturation to autoantibody secreting state requires CD4
T helper cells to recognize human leukocyte antigen (HLA) class II
molecules bound peptides on the surface of B cells and on other
antigen-presenting cells [9]. Concordantly, candidate gene asso-
ciation studies have provided evidence for association of
autoantibodies with HLA class II alleles [10,11]. Outside of these
HLA associations, relatively little is known about the genes
associated with autoantibody production. However, we can
hypothesize that there should be some overlap in the genes and
their alleles that increase the risk of T1D with those that show
association with autoantibody positivity. If autoantibody positivity
per se is not a primary causal factor we should also observe T1D
risk alleles that do not show evidence of association with the
antibodies. We also predict that if a gene variant is associated with
autoantibody positivity, then it becomes a strong candidate as a
risk locus for the associated autoimmune disease. In the present
report we illustrate that this strategy is successful with the
identification of two new candidate genes for Graves’ disease
susceptibility, BACH2 and UBASH3A.
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we measured two T1D-associated anti-islet autoantibodies:
glutamate decarboxylase (GADA, n=2,506) and insulinoma-
associated antigen 2 (IA-2A, n=2,498) in plasma samples from
T1D cases. In contrast with T1D, Graves’ disease is known to be
mediated by autoantibodies against the thyroid stimulating
hormone receptor (TSHR), which leads to hypothyroidism.
However, thyroid peroxidase autoantibodies (TPOA), which are
detected in 75% of Graves’ disease patients [12], are a sensitive
and specific predictor of the disease. TPOA are also correlated
with anti-TSHR autoantibodies and Hashimoto’s thyroiditis [12].
This direct role of anti-TSHR antibodies in Graves’ disease
aetiology motivated the measurement, in the same collection of
T1D cases, of TPOA (n=8,300), which was an assay available at a
significantly lower cost than the anti-TSHR autoantibody test. To
further extend this analysis, we also measured autoantibodies
directed against parietal cells (PCA, n=4,328), a biomarker for
autoimmune gastritis and pernicious anaemia. Eighty-six percent
of pernicious anaemia patients are estimated to be PCA positive
[13].
We combined these four autoantibody measurements (GADA,
IA-2A, PCA and TPOA) with available genome-wide genotype
data to carry out four distinct genome-wide association (GWA)
scans for autoantibody positivity. Outside of the HLA region, we
discovered the association of several genes with autoantibody
positivity, including evidence for association of the ABO blood
gene with autoimmunity and also, surprisingly, a strong associa-
tion of the known autoimmunity gene, FCRL3, with IA-2A, but
not with T1D. Associations with variants in the HLA region are
the subject of a separate paper (Howson et al., Diabetes).
Results
In the 8,506 T1D samples the median age at venepuncture was
13 years, the median age at T1D diagnosis was 8 years and the
median time between T1D diagnosis and venepuncture was 5
years. Thirty percent of the blood samples were taken within two
years. The distribution of the four antibody measurements is
shown in Figure S1. GADA and IA-2A -seropositive cases were at
50% and 59%, respectively (Table 1). Consistent with previous
reports [1], time since diagnosis is negatively correlated with
GADA and IA-2A positivity (Table 1), perhaps reflecting declining
levels of beta-cell antigens and immuno-inflammatory activity
following diagnosis [14]. We, therefore, included time since
diagnosis (or disease duration) as a covariate in all statistical
analysis. After controlling for time since diagnosis, early-onset
T1D cases had lower frequencies of GADA and IA-2A (Table 1).
PCA and TPOA frequencies in the T1D samples were 10% and
12%, respectively (Table 1). Age has been shown to have a major
effect on TPOA frequency [15]. In our study, time since T1D
diagnosis is positively correlated with PCA and TPOA positivity
(Table 1), but because this covariate is strongly correlated with age
at venepuncture (correlation coefficient 0.85), this observation is
most likely a consequence of age. PCA, GADA and TPOA
frequencies were higher in women, a result consistent with
previous reports of elevated frequency of autoimmune diseases in
Author Summary
Autoantibodies are important markers for autoimmune
diseases such as type 1 diabetes and Graves’ disease.
However, little is known about the genetic factors that
control their production. To improve our understanding of
this genetic basis, we measured four autoantibodies in a
collection of up to 8,300 type 1 diabetes cases plasma
samples. We combined these measurements with ge-
nome-wide genotype data to conduct four independent
genome-wide association studies. Two loci showed
unequivocal evidence of autoantibody association: the
FCRL3 locus and the ABO blood group locus. Variants in the
FCRL3 gene have been previously associated with autoim-
mune diseases, but such associations have not been
reported for ABO blood group genotypes. In addition, we
found extensive overlap between type 1 diabetes and
autoantibody loci, and these findings provide new
information about the role of these risk variants. Lastly,
we hypothesized that loci associated with thyroid autoan-
tibodies are strong candidates for association with thyroid
autoimmune disorders. We confirmed this hypothesis by
genotyping these variants in an independent cohort of
Graves’ disease cases, and we found evidence for two new
Graves’ disease loci.
Table 1. Sample size and covariates correlated with autoantibody measurements.
Autoantibody Sample size OR (p-value)
n % pos GWA
Time since
diagnosis
{
Age at
diagnosis Women GADA IA-2A PCA TPOA
GADA 2506 50% 2261 0.66 3.2 1.8 - NS NS 2.1
(6.5e-12) (5.2e-27) (1.1e-11) (1.1e-07)
IA-2A 2498 59% 2254 0.56 2.6 NS NS - NS NS
(2.5e-21) (1.3e-17)
PCA 4328 10% 2205 1.4 NS 1.7 NS NS - 2.9
(5.9e-07) (3.5e-07) (7.8e-17)
TPOA 8300 12% 5781 1.3 NS 2.3 2 NS 2.9 -
(1.1e-11) (1.3e-34) (2.7e-07) (9.5e-17)
p-values and estimated odds ratios (OR) for the effect of covariates on autoantibody measurements (logistic regression controlling for other significant covariates). The
sample size, n, refers to the number of samples with autoantibody data. For time since diagnosis and age at diagnosis, odds ratios are reported for a 10 year difference.
GWA indicate the total number of samples genotyped either on the AffymetrixGeneChip Human Mapping 500 K or Illumina 550 K arrays with autoantibody data.
{: Time since diagnosis is highly correlated with patient’s age at venepuncture (correlation coefficient r=0.85). NS: Non significant (p.0.01).
doi:10.1371/journal.pgen.1002216.t001
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significant positive correlations were observed between PCA and
TPOA, and between TPOA and GADA (Table 1).
Analysis of the 1q23/FCRL1-FCRL3 region
We found two (non-MHC) associations using a genome-wide
significance threshold of, p=5 610
28. Firstly, we associated
rs4971154 on chromosome 1q23 in exon 5 of the immune-
regulatory receptor gene FCRL1 with IA-2A (p=2.9610
211,
estimated odds ratio (OR)=0.66 for the minor allele C, Table 2).
Three other loci in this chromosome region have been associated
with autoantibody and/or autoimmune diseases: rs7528684,
located in the promoter region of the FCRL3 gene, was associated
with rheumatoid arthritis (RA) and SLE risk, as well as frequency
of cyclic citrullinated peptide autoantibodies (CCPA) in Japanese
RA patients [18]. rs11264798 located in intron 8 of FCRL3, and
rs10489678 in FCRL5, have been previously associated with
Graves’ disease [19].
To understand the relationship between the TPOA, IA-2A,
T1D and Graves’ disease associations at the 1q23 locus, we
genotyped rs4971154, rs7528684, rs11264798 and rs10489678 in
the full T1D case-control collection (up to 10,596 controls and
8,506 T1D cases), as well as in 2,477 Graves’ disease patients (the
same cohort that was used in [19]). We used stepwise logistic
regression to select the most associated SNP for each of the four
traits. The alleles, minor allele frequencies and pairwise measures
of LD are shown in Table S1. Association results for these SNPs
with IA-2A and T1D are shown in Table 3. TPOA and Graves’
results are shown in Table 4.
We found that the IA-2A association in T1D cases was fully
accounted for by the FCRL3 SNP rs7528684 (p=8.3610
212,
OR=0.65 for the minor allele C, Table 3), which added to other
single SNP models in the stepwise regression (p,0.01). rs7528684
was denoted as 169CRT in [18], where Kochi et al. reported that
the RA and SLE risk allele rs7528684-C was also associated with
increased FCRL3 expression and higher CCPA frequency in RA
patients. In our European sample sets, the minor allele of
rs7528684 is C and was strongly negatively associated with IA-2A
positivity, a direction of effect opposed to the previously reported
CCPA result. We checked this result thoroughly by resequencing
both alleles in four selected samples and verified the initial data (Y.
Kochi, personal communication), but found no errors. We also
replicated the IA-2A/rs7528684 in 3,897 affected siblings from
multiplex families (Methods) and found consistent evidence of IA-
2A negative association (p=7.6610
29, OR=0.69).
The TPOA and Graves’ disease associations showed the same
pattern of association, whereby a single (although different) SNP,
rs11264798, alone explained both associations (p=3.5610
24 for
TPOA and p=1.7610
23 for Graves’ disease, Table 4). The SNP
rs11264798 added to other single SNP models in a stepwise
regression (p,0.01). The discrepancy between the TPOA and IA-
2A results suggests that the causal variants underlying these two
associations are distinct. We confirmed this hypothesis using a
formal statistical test [20] (p=0.004 against the null hypothesis of a
single causal variant).
In contrast with the IA-2A and TPOA/Graves’ disease result,
there was no evidence for T1D case-control association in this
region: p=0.09 for rs7528684 and p=0.06 for rs11264798 in
10,010 controls and 8,327 T1D cases, estimated OR=0.97 and
1.04, respectively, for the minor alleles (Table 3). To evaluate this
result further we genotyped both SNPs in a set of 8,038 T1D trios
(3,598 multiplex families, see Methods), obtaining weak evidence
of T1D association (p=0.026 for rs7528684 and p=0.04 for
rs11264798, with relative risks 0.95 and 1.04, respectively). Taken
together, these data suggest that the minor allele C of rs7528684 is
very weakly protective for T1D (combined p=0.0013, OR=0.95)
and the minor allele C of rs11264798 increases T1D risk very
slightly (combined p=0.0014, OR 1.04). The rs11264798-C
minor allele is protective for TPOA, but is also in LD with the
rs7528684-T major allele associated with IA-2A positivity.
PCA association at the 9q34/ABO locus
PCA positivity was associated with rs657152 (G.T) on
chromosome 9q34, in intron 1 of the blood group gene ABO
(p=1.15610
213, OR=0.35 for the minor allele T, Table 2).
rs657152-G is a marker for the ABO blood group O in Caucasian
individuals (using blood group frequency estimates based on
rs6872889 in [21], which is a proxy for rs657152, HapMap
r
2=0.93). We found a departure from the linear trend test
assumption for this SNP (p=0.02 when we compared a 2 degree-
of-freedom genotype effect model to the standard 1 degree-of-
freedom linear trend test). Taking the most common genotype GG
as reference the estimated odds ratios were 0.26 for GT (95% CI:
0.17–0.39) and 0.23 for TT (95% CI: 0.11–0.49). Therefore in this
dataset the observed PCA association is essentially a consequence
of the elevated PCA frequency in the GG genotype group, which is
closely correlated to the ABO blood group O.
The major allele G at this SNP, associated with higher PCA
frequency in T1D cases, has also been associated with multiple
traits including higher circulating levels of soluble intercellular
adhesion molecule 1 (sICAM-1, [21]) and E-selectin [22], higher
gastric ulcer risk [23] and lower pancreatic cancer risk [24],
indicating that this blood group determinant enzyme has
pleiotropic effects. We found no association of this SNP with
T1D (p=0.268 in 7,240 controls and 5,817 T1D cases). We
investigated whether other sICAM associated SNPs in a different
chromosome region (19p13, [21]) showed association with PCA
(Table S2), but found no evidence supporting this.
At the FUT2 gene locus, the A allele of rs601338A.G
(X143W/se428) prevents the secretion of ABO antigens in the
gut and in saliva. The homozygous genotype AA has recently been
associated with susceptibility for Crohn’s disease [25,26] and to
Table 2. Autoantibody associations passing a genome-wide association significance threshold in the GWA scan (MHC excluded).
SNP Chr Gene Alleles MAF N p-value OR [95%CI]
IA-2A rs4971154 1q23 FCRL1 T.C 0.49 970/1385 2.9e-11 0.66 [0.58–0.74]
PCA rs657152 9q34 ABO G.T 0.35 1768/158 1.15e-13 0.34 [0.25–0.47]
Non-MHC SNPs passing a genome-wide significance threshold p,5610
28 when scanning the genome for association with IA-2A, GADA, PCA, and TPOA. p-values and
odds ratios (OR, estimated for the minor allele and 95% confidence intervals (CI)) were obtained using logistic regression (1 df trend test). We controlled for significant
covariates (sex, time since diagnosis and age at bleed). The sample size N indicates the number of autoantibody negative/positive individuals. Antibody status was
coded as a binary variable (Methods). Note that we listed the nearest gene, which does not imply that this gene is causal.
doi:10.1371/journal.pgen.1002216.t002
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therefore tested a potential PCA association with this SNP. We
found unconvincing evidence of PCA association: p=0.077 linear
trend test in 437 PCA positive and 3,697 PCA negative samples,
estimated OR=0.88 (95% CI: 0.77–1.01) for the G allele. Taking
the AA non-secretor group as reference, a genotype association
analysis suggests that the estimated ORs are not significantly
different for the AG (OR=0.81, 95% CI: 0.64–1.01) and GG
(OR=0.79, 95% CI: 0.796–1.05) genotype groups. Therefore,
while the evidence is unconvincing for PCA, this recessive model
of increased risk for non-secretor AA genotype group is consistent
with the T1D and Crohn disease associations.
Autoantibody association at T1D loci
We then used additional genotyping data in the full T1D case
collection to investigate autoantibody associations at 64 known
T1D-associated SNPs in 52 distinct chromosome regions ([27],
www.t1dbase.org). Owing to higher prior belief that these SNPs
are autoantibody associated we used a less stringent threshold
(p#0.01) corresponding here to a false discovery rate of 16%
(Benjamini-Hochberg estimation procedure [28]). We identified
13 independent associations, which included two SNPs associated
with two distinct autoantibodies each (Table 5). The most
significant finding was the TPOA association with the BACH2
T1D-associated SNP rs11755527 (C.G, p=9.7610
27,
OR=1.27). Eight out of these 13 associations involved TPOA.
The association of TPOA with CTLA4 in T1D cases has been
reported previously [16], and here, we extend support for this
finding. We did not replicate a previously published GADA/
PTPN22 interaction [29]. We also did not obtain evidence of
association with any of the autoantibodies (p.0.05), including IA-
2A and GADA, with INS, which shows the strongest association
with T1D outside of the MHC region.
To replicate both IA-2A associations in an independent
collection, we genotyped the IL27 SNP rs4788084 and IFIH1
SNP rs1990760 in the 3,897 T1DGC affected sibling samples with
IA-2A data (Methods). Both SNPs convincingly replicated the
initial IA-2A results: two-tailed p=0.0074, 8.4610
24 for IFIH1/
rs1990760, IL27/rs4788084, respectively, with the direction of
effect consistent in both cases with the initial finding (estimated
OR=1.13 for IFIH1 and 1.17 for IL27).
Graves’ disease association for newly identified TPOA loci
TPOA are commonly detected in Graves’ disease patients and,
therefore, the TPOA- associated SNPs located in the genes
RASGRP1, UBASH3A and BACH2 that have not been previously
tested for Graves’ disease association are strong Graves’ disease
candidates. To investigate this hypothesis we genotyped these
three SNPs in 2,477 Graves’ disease cases (Table 4). We obtained
p=2.4610
24, OR=1.14 for the UBASH3A C.A SNP rs3788013
and p=6.2610
23, OR=1.11 for the BACH2 C.G SNP
rs11755527. For both SNPs the minor allele is the risk allele for
Graves’ disease and T1D and was associated with higher positivity
for TPOA. No evidence of Graves’ disease association was found
for rs7171171 in RASGRP1 (p.0.05).
Analysis of additional autoimmune associated findings
Given the positive findings in T1D associated loci we extended
our analysis to 135 SNPs in 100 autoimmune-associated loci
[30,31,32]. Each SNP was tested for association with TPOA,
GADA, PCA and IA-2A using p#0.01 as a threshold (false
discovery rate of 27%, Table S3). We found five additional
associations: 2q37/PDCD1-IA-2A, 3p14.3/PXK-GADA, 5q33.3/
IL12B-TPOA, 12q12/LRRK2-TPOA, 12q24.31/SPPL3-TPOA.
We genotyped the full T1D case-control collection as well as the
set of Graves’ disease cases to validate the three TPOA findings,
Table 3. T1D and IA-2A association results in the 1q23/FCRL3 gene region.
IA-2A T1D
SNP Alleles IA-2A pos IA-2A neg OR [95% CI] p T1D Controls OR [95% CI] p
rs4971154 C 0.44 0.54 0.66[0.58–0.74] 2.9e-11 0.48 0.498 0.95[0.91–0.99] 0.013
TT 429 (0.31) 203 (0.21) 1 - 2231 (0.27) 2508 (0.25) 1 -
CT 682 (0.49) 489 (0.5) 0.67[0.54–0.82] 6.2e-05 4182 (0.5) 5133 (0.51) 0.92[0.85–0.98] 0.014
CC 274 (0.2) 278 (0.29) 0.43[0.34–0.55] 2.4e-10 1974 (0.24) 2477 (0.24) 0.9[0.83–0.97] 0.0087
rs7528684 C 0.4 0.5 0.65[0.58–0.74] 8.3e-12 0.44 0.46 0.97[0.93–1.01] 0.09
TT 514 (0.36) 251 (0.25) 1 - 2669 (0.31) 3151 (0.3) 1 -
CT 676 (0.47) 519 (0.51) 0.66[0.54–0.82] 2.8e-06 4213 (0.49) 5246 (0.5) 0.96[0.9–1.02] 0.21
CC 240 (0.17) 246 (0.24) 0.43[0.34–0.55] 4.6e-10 1714 (0.2) 2199 (0.21) 0.93[0.86–1.01] 0.11
rs11264798 C 0.53 0.46 1.42[1.26–1.61] 1.9e-8 0.5 0.49 1.04[1–1.08] 0.06
GG 307 (0.22) 287 (0.29) 1 - 2148 (0.25) 2670 (0.26) 1 -
CG 708 (0.5) 501 (0.51) 1.41[1.14–1.73] 0.0057 4215 (0.5) 5066 (0.5) 1[0.96–1.1] 0.35
CC 397 (0.28) 199 (0.2) 2.02[1.6–2.6] 1.8e-07 2121 (0.25) 2381 (0.24) 1.1[1–1.2] 0.014
rs10489678 A 0.17 0.21 0.77[0.66–0.89] 6.6e-4 0.18 0.19 0.95[0.91–1.01] 0.078
GG 967 (0.69) 625 (0.63) 1 - 5656 (0.67) 6623 [0.65) 1 -
AG 381 (0.27) 313 (0.32) 0.75[0.62–0.91] 0.0091 2485 (0.29) 3124 (0.31) 0.93[0.87–0.99] 0.028
AA 49 (0.035) 49 (0.05) 0.63[0.41–0.96] 0.036 308 (0.036) 368 (0.036) 0.98[0.84–1.15] 0.8
Genotypic and allelic IA-2A/T1D association results for the four SNPs in the 1q23/FCRL3 region genotyped in the full JDRF/WT T1D case control collection. For each SNP
the first row indicates the minor allele for which the odds ratio (OR) is estimated (95% confidence intervals (CI) is shown between brackets). IA-2A association tests
include age at venepuncture, age at T1D onset and region of origin as covariates. T1D tests only include region of origin. For the genotypic association the most
common homozygous group was taken as the reference. Numbers in parenthesis indicate the frequency of this genotype or allele.
doi:10.1371/journal.pgen.1002216.t003
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evidence of Graves’ disease or T1D association (p.0.05).
Discussion
The combination of genome-wide genotyping data with
autoantibody measurements and case-control data for T1D and
Graves’ disease has enabled the discovery of several new genetic
associations with autoantibody positivity and disease traits. We
conclude that the nine loci (FCRL3, RASGRP1, SH2B3, STAT4,
BACH2, UBASH3A, IL2, PTPN22, and CTLA4) associated with
TPOA, which is not a T1D anti-islet autoantibody, may have
general effects in adaptive immunity, in the complex interactions
between antigen presenting cells and T cells leading to antibody-
producing plasma B cells. Consistent with this general role in
autoimmunity, six out of nine TPOA loci were associated with
Graves’ disease (except rs2069762 in IL2, rs3184504 in SH2B3
and rs7171171 in RASGRP, Table 5), including both newly
identified Graves’ disease loci BACH2 and UBASH3A. For these six
TPOA/Graves’ disease-associated SNPs, the Graves’ disease risk
allele is also the one associated with elevated frequency of TPOA.
Lastly, four of the nine TPOA associated SNPs (in SH2B3, CTLA4,
BACH2 and UBASH3A) have also been associated with celiac
disease [33] (but not the SNPs in RASGRP1, STAT4, PTPN22, IL2
[20] and FCRL3 [33]). We note that the Graves’ disease associated
thyroglobulin (TG) gene region, was not associated with TPOA
(p.0.01 at all SNPs within 300 kb of the TG gene). To further
understand the association of genes with autoantibodies in T1D
and in Graves’ disease the measurement of TSHR autoantibodies
will be informative.
After controlling for time since diagnosis we found that the
patients’ age at T1D diagnosis was positively correlated with the
presence of GADA and IA-2A, such that patients diagnosed at a
younger age are less likely to be IA-2A or GADA positive. This
result is consistent with other studies that found that GADA
positivity was associated with older age at diagnosis [34,35]. Our
finding suggests that earlier onset T1D involves pathogenesis
directed towards autoantigens other than GADA/IA-2A, and/or
beta-cell destruction is so profound in these children that they lose
their autoantibodies very rapidly owing to extensive removal of
islet antigens following T1D onset.
Owing to the fact that the plasma samples in this study were
collected a median time of five years following diagnosis, with 30%
within 2 years of diagnosis, we cannot exclude the possibility that
the same GWA conducted using autoantibody data closer or prior
to T1D onset might yield different results. Nevertheless, the
prevalences of GADA and IA-2A in our study (Table 1) are
consistent with previously reported measurements in paediatric
Table 4. T1D, TPOA, and Graves’ disease associations for SNPs genotyped in the Graves’s disease cohort.
SNP Chr. Gene Alleles p T1D OR T1D p Graves OR Graves p TPOA OR TPOA
rs2476601 1p13.2 PTPN22 C.T 2.1e-111 1.9–2.1 2.2e-14 1.4–1.7 2.1e-05 1.2–1.4
rs11264798 1q23.1 FCRL3 G.C - - 0.0017 0.83–0.96 0.00035 0.74–0.94
rs4971154 1q23.1 FCRL1 T.C 0.013 0.91–0.99 0.0011 1–1.2 0.0033 1.1–1.3
rs7528684 1q23.1 FCRL3 T.C - - 0.0039 1–1.2 0.02 1–1.2
rs10489678 1q23.1 FCRL5 G.A ------
rs1990760 2q24.2 IFIH1 A.G 2.2e-14 0.81–0.89 - - - -
rs3087243 2q33.2 CTLA4 C.T 2.3e-17 0.79–0.87 1e-21 0.66–0.76 0.0011 0.73–0.95
rs2069762 4q27 IL2-IL21 T.G 5.4e-07 0.84–0.93 - - 0.0045 1.1–1.3
rs2069763 4q27 IL2-IL21 G.T 7.4e-08 1.1–1.2 0.026 0.85–0.99 - -
rs6822844 4q27 IL2-IL21 G.T 0.034 0.89–1 - - - -
rs6897932 5p13.2 IL7R C.T 0.0026 0.89–0.98 - - - -
rs6887695 5q33 IL12B G.C ------
rs11755527 6q15 BACH2 C.G 3.1e-08 1.1–1.2 0.0062 1–1.2 9.7e-07 1.2–1.4
rs1738074 6q25.3 TAGAP G.A 0.00051 0.89–0.97 0.049 0.86–1 - -
rs11594656 10p15.1 IL2RA T.A 2e-06 0.84–0.94 0.00028 0.78–0.93 - -
rs689 11p15.5 INS A.T 5.2e-196 0.38–0.49 - - - -
rs11175593 12q12 LRRK2 C.T 0.028 1–1.4 - - - -
rs2292239 12q13.2 ERBB3 C.A 2.9e-27 1.2–1.3 - - - -
rs662739 12q24.31 SPPL3 G.A - - 0.0086 0.84–0.97 0.011 1–1.2
rs3184504 12q24.12 SH2B3 C.T 2e-38 1.3–1.4 - - 0.003 1.1–1.3
rs7171171 15q14 RASGRP1 A.G 2.3e-7 1.09–1.2 - - 0.0004 0.71–0.91
rs12708716 16p13.13 CLEC16A A.G 5e-14 0.8–0.89 - - - -
rs478582 18p11.21 PTPN2 T.C 2.8e-12 0.82–0.9 0.011 0.84–0.98 - -
rs763361 18q22.2 CD226 C.T 1.3e-09 1.1–1.2 0.045 1–1.2 - -
rs3788013 21q22.3 UBASH3A C.A 1e-07 1.1–1.2 0.00024 1.1–1.2 0.00099 1.1–1.3
T1D, Graves’ disease, and TPOA association results for the set of SNPs that were typed in the Graves’ disease cohort (2,477 cases). 95% confidence intervals are shown for
the minor allele (1 df linear trend tests stratified by region of origin in the UK). When p.0.05, 95% confidence intervals for the odds ratio (OR) and p-values are not
shown. We list the closest gene that may not be the causal one. In particular recent data (Cooper et al., submitted) show that the rs689732/IL7R is secondary to a SNP
located in the CAPSL gene.
doi:10.1371/journal.pgen.1002216.t004
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autoantibody status in T1D cases may lower the statistical power
but it is highly unlikely to generate false positive genetic
associations. Hence, the convincing association results identified
in this study (Table 2, Table 3, Table 4, Table 5) indicate that
these measurements are valid.
Our estimated TPOA frequencies are consistent with a recent
large scale study [17] which found 8.8% of T1D children aged less
than 12 years to be TPOA positive. However, the strong effect of
age, and the use in other studies of different assays with variable
sensitivity, complicates a comparison of autoantibody frequency
with healthy control groups. A previous study [39] found 2.6% of
Finnish school children and 0.4% of Russian school children to be
TPOA positive but another Swedish study [40] found 11.3% of 12
year old children to be TPOA positive. Our frequency of PCA
positivity in plasma samples from T1D cases of 10% is comparable
to previous reports of PCA frequencies in T1D diagnosed under
age 30 years (9% in [41]), but higher in that the 2.2% in
population controls aged 21–30 years [41].
Among the four autoantibodies we considered, the absence of
correlations between IA-2A and GADA/PCA/TPOA (Table 1)
suggests the involvement of distinct genes and pathways for IA-2A.
Moreover, for the T1D-associated SNPs located in IFIH1 and
IL27, the T1D risk allele is associated with reduced IA-2A
positivity (Table 5). This result is different from the TPOA/T1D
associations for which, in six out of eight cases, the T1D risk allele
is also the allele associated with increased TPOA positivity
(rs7171171 in RASGRP1 and rs2069762 in IL2 being the
exceptions, see Table 5). This pattern has been reported previously
between IA-2A and the T1D associated HLA-A*24 allele [36] and
confirmed by our recent analyses (JMMH, JAT, Diabetes).
The 1q23/FCRL3 association data highlight the complexity of
this autoimmune locus, which has previously been associated with
SLE, RA and Graves’ disease. Our results show that two distinct
associations co-localize in this chromosome region. Firstly, the
SNP rs7528684-C is associated with SLE and RA risk, CCPA
positivity in RA patients, but is negatively associated with IA-2A
positivity in T1D. These associations, which are in opposite
directions for IA-2A compared to the other autoimmune traits,
contrast with the consistency observed for the PTPN22 and
CTLA4 variants, for which the risk allele is consistently the same
across multiple autoimmune diseases (in particular Graves’
disease, T1D and TPOA in T1D patients, see Table 4). Secondly,
the SNP rs11264798-G is independently associated with Graves’
disease, as well as with TPOA positivity in T1D patients. The
three autoantibody associations in this chromosome region (with
CCPA, IA-2A and TPOA) indicate that this locus is involved in
the breakdown of self-tolerance and autoantibody production.
On the other hand, the effect on T1D risk is not strong
(combined case-control and family p=0.001). Owing to the
involvement of this region in multiple autoimmune disorders the
prior belief that this locus is T1D associated is high. Therefore,
the T1D association result could be real, but the effect size very
small (estimated odds ratio 1.05). One explanation for these
highly significant results in terms of IA-2A association is that the
autoimmune disease-associated allele, C (of SNP rs7528684) is
Table 5. Autoantibody associations at published T1D associated loci.
T1D GADA IA-2A PCA TPOA
SNP Chr Gene All
OR
[95% CI] p
OR
[95% CI] p
OR
[95% CI] p
OR
[95% CI] p
OR
[95% CI]
rs2476601 1p13.2 PTPN22 C.T2
[1.88–2.13]
- - - - - - 2.07e-05 1.3
[1.15–1.46]
rs1990760 2q24.2 IFIH1 A.G 0.848
[0.81–0.89]
- - 0.0036 1.2
[1.06–1.36]
0.000699 0.772
[0.66–0.9]
--
rs7574865 2q32.3 STAT4 G.T1 . 1
[1.04–1.15]
- - - - - - 0.01 1.16
[1.04–1.3]
rs3087243 2q33.2 CTLA4 C.T 0.829
[0.79–0.87]
- - - - - - 0.00113 0.839
[0.75–0.93]
rs2069762 4q27 IL2 T.G 0.889
[0.85–0.93]
- - - - - - 0.00452 1.17
[1.05–1.3]
rs11755527 6q15 BACH2 C.G 1.13
[1.08–1.17]
- - - - - - 9.67e-07 1.27
[1.15–1.4]
rs12722495 10p15.1 IL2RA A.G 0.618
[0.57–0.67]
0.00658 0.734
[0.59–0.92]
-- -- --
rs3184504 12q24.12 SH2B3 C.T 1.32
[1.27–1.38]
0.00175 1.21
[1.07–1.36]
- - - - 0.003 1.16
[1.05–1.28]
rs7171171 15q14 RASGRP1 A.G 1.14
[1.09–1.2]
- - - - - - 0.0004 0.8
[0.71–0.91]
rs4788084 16p11.2 IL27 G.A 0.879
[0.84–0.92]
- - 0.00305 1.21
[1.07–1.37]
-- --
rs3788013 21q22.3 UBASH3A C.A 1.12
[1.07–1.17]
- - - - - - 0.000991 1.18
[1.07–1.29]
Tests of 64 confirmed T1D susceptibility SNPs (located in 52 distinct chromosome regions, see www.t1dbase.org) for autoantibody association (p#0.01, false discovery
rate 16%). SNPs without any positive autoantibody association are not shown. The full JDRF/WT T1D case-control collection was used (up to 10,596 controls and 8,506
T1D cases, n=2,506 for GADA, n=2,498 for IA-2A, n=4,328 for PCA and n=8,300 for TPOA). p-values and odds ratio (OR) and 95% confidence interval (CI) for the minor
allele are computed using logistic regressions independently for each SNP (1 df trend test) controlling for significant covariates (sex, time since diagnosis and age at
diagnosis). Autoantibody status was coded as a binary variable (Methods).
doi:10.1371/journal.pgen.1002216.t005
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autoantibody responses to this antigen [42]. The FCRL3
molecule could be affecting T regulatory cell development or
function [43].
The ABO gene encodes a glycosyltransferase which is expressed
in multiple human tissues. It could affect glycosylation, and
therefore function or antigenicity of a wide range of molecules, in
particular parietal cells antigens in the gastro-intestinal mucosal
lining [44]. This blood group O, associated with increased PCA
frequency, is also associated with increased frequency of gastric
ulcers [23], a condition frequently caused by long-standing
Helicobacter pylori infection. ABO blood groups are not associated
with the presence of H. pylori [45] but the blood group O has been
associated with increased inflammatory response to this bacterium
[46]. A plausible hypothesis for the ABO-PCA association is that
the inflammation caused by H. pylori can not only result in gastric
ulcers, but can also initiate an autoimmune reaction directed
against parietal cells. However, previous reports do not support an
increased pernicious anaemia risk for individuals with the ABO
blood group O [47,48,49], which indicates that the role of ABO in
progression from PCA to pernicious anaemia is not straightfor-
ward.
Finally, we note that the majority of T1D regions did not
associate with autoantibody positivity. Many of these chromosome
regions contain genes of unknown function with no obvious
candidate genes. It will be informative to continue to compare
genetic associations from other diseases and traits (such as
autoantibodies analysed here and other serum analytes, such as
soluble CD25 [50]), to identify which of these newly-mapped,
unexplored T1D loci are involved in certain pathways. Our
current results place the candidate genes SH2B3, CTLA4, BACH2
and UBASH3A at the very heart of the immune response in the
pathogenesis of both T1D and celiac disease.
Material and Methods
T1D cases and autoantibody measurements
9,381 T1D case samples (DNA and plasma) were available as
part of the Juvenile Diabetes Research Foundation/Wellcome
Trust Diabetes and Inflammation Laboratory type 1 diabetes case
GRID (Genetic Resource Investigating Diabetes) collection (white
British individuals diagnosed before age 17). Autoantibodies were
measured in plasma for a subset of them (GADA, n=2,506, IA-
2A, n=2,498, PCA, n=4,328, TPOA, n=8,300).
Presence of each of the autoantibodies (IA-2A, GADA) in the
type 1 diabetes cases was tested using plasma stored at 280uCi n
aliquots. Autoantibodies to GAD and IA-2A were measured in the
Department of Clinical Science at North Bristol, University of
Bristol, using a radioimmunoassay [51]. GADA sensitivity was
86% and specificity 99%, while IA-2A sensitivity was 72% and
specificity 93% in the Diabetes Antibody Standardization
Program 2005 (23). Presence of GADA and IA-2A was taken as
above 14 and 6 WHO Units/ml, respectively, which corresponds
to the 97.5
th percentile of the distribution of these autoantibodies
in 2,860 school children from Oxford, UK [51].
TPOA and PCA were measured by the Department of Clinical
Biochemistry, University of Cambridge with, respectively, a
PLATO processor ELISA immunoassay (Phadia, Milton Keynes,
UK) using recombinant TPO antigen standardised against the
National Institute of Biological Standards and Controls standard
serum 66/387 in which the positivity threshold for TPOA was
85 IU/ml, and ELISA manufactured by Phadia and analysed on a
QIAGEN Plato III platform in which the threshold for presence of
PCA was 10 U/ml.
Type 1 diabetes affected sib-pair families
To follow-up on a T1D association observed in the case-control
data we genotyped 3,598 affected sib-pair families. The majority
was available through the Type 1 Diabetes Genetics Consortium
(T1DGC; http://www.t1dgc.org; http://www-gene.cimr.cam.ac.
uk/todd/dna-refs.shtml). Of these T1DGC families: 237 were
from the T1DGC Asia–Pacific region, 580 from T1DGC North-
America and 1,103 from T1DGC-Europe. In addition, 354
families originated from the UK-Warren collection, 298 from
HBDI (http://www.ndriresource.org/NDRI_Initiatives/HBDI/
36/) and 1,026 from Finland. These samples were used for T1D
association testing and IA-2A was the only autoantibody data
available. As for the T1D case control samples, autoantibodies
were measured on average several years after T1D diagnosis.
Graves’ disease cases
To test for association with Graves’ disease, a total of 2,477
unrelated white ethnic group, British Graves’ disease patients were
recruited as part of the autoimmune thyroid disease UK National
Collection. Patients were recruited from centres across England
and Wales including Birmingham, Bournemouth, Cambridge,
Cardiff, Exeter, Leeds, Newcastle and Sheffield. All recruiting
centres used standard clinical criteria to diagnose Graves’ disease
to avoid any clinical heterogeneity. These samples were solely used
to test for Graves’ disease association and no autoantibody data
was available.
Control samples
To test for disease association (T1D and Graves’ disease) control
samples consisted of individuals from the British 1958 Birth
Cohort and UK blood donors National Health Service Blood and
Transplant [19]. Controls were matched to cases using place of
recruitment for each of 12 geographical regions of Great Britain
(Southern England, South-Western England, South-Eastern
England, Eastern England, London, Midlands, Wales, North-
Eastern England, North Midlands, East and West Ridings,
Northern England, Scotland). All cases and controls were of self-
reported white ethnicity. All DNA samples (T1D cases, Graves’
cases and controls) were collected with approval from the relevant
research ethics committee and written informed consent was
obtained from the participants or their guardians. No autoanti-
body data were available for control samples.
Genotyping
Most of T1D cases with autoantibody data were genotyped
previously using the Affymetrix 500K mapping array [19] or the
Illumina 550K array [27]. We combined data from both arrays
using an imputation procedure [27] to carry out a genome-wide
scan for autoantibody association (n=2,261 for GADA, n=2,254
for IA-2A, n=2,205 for PCA, n=5,781 for TPOA).
Statistical analysis
Association between variants and autoantibodies were tested
using regression models, treating positive autoantibody status as a
binary outcome and using a one-degree-of-freedom trend test
(log-scale additive disease model). Significant covariates were
included (sex, time since diagnosis and age at bleed, age at
diagnosis of T1D). Similar analysis was performed to test for T1D
and Graves’ disease association. Geographical region was
included as a confounder in all logistic regression models.
Statistical analyses were performed using the R statistical
software.
Genetics of Autoantibodies in T1D
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Figure S1 Histograms of the four log-transformed autoantibody
measurements : IA-2A, GADA, PCA, TPOA. The vertical red
dashed lines indicate the positivity cut-offs. Details on experimen-
tal design are provided in Material and Methods.
(PDF)
Table S1 Alleles (X.Y, where Y is the minor allele), minor
allele frequency (MAF) and pairwise pattern of linkage disequilib-
rium in UK controls for the four SNPs with published
autoantibody and/or disease association in the FCRL3 chromo-
some region. The notation x/y refers to the standard r
2/D9 values
for pairwise measures of linkage disequilibrium.
(PDF)
Table S2 PCA and sICAM association p -values [21] for SNPs
associated with sICAM at a genome-wide significance levels and
not located in or near the ABO gene. SNPs are taken from Table 1
in [21]. All SNPs are located in the 19p13.2 chromosome region.
(PDF)
Table S3 Genome-wide scan p-values and estimated minor
allele odds ratios (OR) for GADA, IA-2A, PCA, TPOA and T1D
associations for 135 SNPs associated with other autoimmune
disorders [30,31] (excluding SNPs in the HLA locus or that are
only T1D associated). When available, we used follow-up
genotyping data in the maximum available sample size in the
JDRF/WT T1D case control collection. The symbol * indicates
that the SNP has been associated with systemic lupus erythema-
tosus (see [31,32]). Only p-values and odds ratios more significant
than 0.01 are shown (false discovery rate of 27%).The column
Gene only refers to the nearest, or most likely candidate gene, and
in most cases the causal gene may actually differ.
(PDF)
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